Head to Head Analysis: Bayer (BAYRY) & GlycoMimetics (GLYC)

Share on StockTwits

Bayer (NASDAQ: GLYC) and GlycoMimetics (NASDAQ:GLYC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Earnings & Valuation

This table compares Bayer and GlycoMimetics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bayer $39.55 billion 1.84 $8.29 billion $1.90 11.56
GlycoMimetics $20,000.00 31,799.81 -$33.28 million ($1.13) -13.07

Bayer has higher revenue and earnings than GlycoMimetics. GlycoMimetics is trading at a lower price-to-earnings ratio than Bayer, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

0.8% of Bayer shares are held by institutional investors. 43.8% of GlycoMimetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for Bayer and GlycoMimetics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bayer 0 1 4 0 2.80
GlycoMimetics 0 0 5 0 3.00

GlycoMimetics has a consensus price target of $28.00, suggesting a potential upside of 89.57%. Given GlycoMimetics’ stronger consensus rating and higher possible upside, analysts clearly believe GlycoMimetics is more favorable than Bayer.


Bayer pays an annual dividend of $0.57 per share and has a dividend yield of 2.6%. GlycoMimetics does not pay a dividend. Bayer pays out 30.0% of its earnings in the form of a dividend.


This table compares Bayer and GlycoMimetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bayer 11.62% 17.78% 7.84%
GlycoMimetics N/A -23.05% -21.99%

Risk and Volatility

Bayer has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, GlycoMimetics has a beta of 3.23, suggesting that its share price is 223% more volatile than the S&P 500.


Bayer beats GlycoMimetics on 8 of the 15 factors compared between the two stocks.

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, and cosmetics in the dermatology, nutritional supplement, analgesic, digestive health, allergy, cold, foot care, and sun protection categories. The Crop Science segment offers crop protection products, seeds, non-agriculture pest control products. The Animal Health segment develops and markets products and solutions for the prevention and treatment of disease in companion and farm animals to vets, farmers, and pet-owners. Bayer Aktiengesellschaft has a collaboration agreement with The University of Texas MD Anderson Cancer Center to develop cancer treatments, as well as Haplogen GmbH. The company was founded in 1863 and is headquartered in Leverkusen, Germany.

About GlycoMimetics

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc. The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma. It is also developing a Phase 1 clinical trial drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. It has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply